Business
Theravance Biopharma to Present at Two Upcoming Investor Conferences
DUBLIN, Nov. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in fireside chats at two
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"DUBLIN, Nov. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in fireside chats at two upcoming investor conferences:\n\n \nEvercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 9:30 a.m. ET. The conference will be held December 3-5 at the Four Seasons Boston. Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 at 8:00 a.m. ET. The conference will be held December 3-5 at the Lotte New York Palace Hotel.A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software. Audio replays will be available for 30 days following the presentation. \nAbout Theravance Biopharma\nTheravance Biopharma, Inc. (\"Theravance Biopharma\") is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused in the areas of inflammation and immunology.\nIn pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant patient needs.\nWe have an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY ELLIPTA. \nFor more i...